Lucid Diagnostics (LUCD) FY 2025 Annual General Meeting June 18, 2025 11:00 AM ET Speaker0 call the Annual Meeting of Stockholders of Lucid Diagnostics Incorporated to order. I'm Vishal Rishan Aklog, our Chairman and Chief Executive Officer. Also President of Denison and McGrath, our Chief Financial Officer Jim Dong of CDIZ CPAs, our auditors Eric Schwartz of Grabbard Miller, our outside counsel and Allen Burton of Continental Stock Transfer and Trust Company, our transfer agent. Mr. Schwartz will act as se ...

Vertiv (VRT) FY 2025 Annual General Meeting June 18, 2025 11:00 AM ET Speaker0 Good day, and welcome to the Veritiv Holdings Co. Annual Meeting of Stockholders. I would now like to turn the conference over to Dave Cote, Executive Chairman of Veritiv. Please go ahead. Speaker1 I'm Dave Cody, the executive chairman of the board, and I'm calling to order our twenty twenty five annual shareowners meeting. Information regarding the agenda, rules of conduct, and technical support for the meeting can be found on y ...

CrowdStrike (CRWD) FY 2025 Annual General Meeting June 18, 2025 11:00 AM ET Speaker0 Morning, everyone, and thank you for your participation today. My name is Will Zelver, CrowdStrike's Director of Investor Relations. I'm pleased to welcome you to CrowdStrike's twenty twenty five Annual Meeting of Stockholders. Momentarily, CrowdStrike's President, CEO and Member of the Board, George Kurtz, will say a few words. George's remarks and any answers to questions may include forward looking statements. Actual eve ...

Sarepta Therapeutics TodaySRPTSarepta Therapeutics$21.56 +0.00 (+0.02%) 52-Week Range$18.30▼$173.25Price Target$70.76Add to WatchlistIn another tragic incident, Sarepta Therapeutics NASDAQ: SRPT saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute liver failure (ALF) after doctors treated them with ELEVIDYS. Sadly, the same thing happened three months ago. As a result, Sarepta has suspended shipments of ELEVIDYS for non-ambulat ...

公司动态 - 吉利德科学公司正在接受Pomerantz律师事务所的调查，涉及证券欺诈或其他非法商业行为的指控 [1] - 美国食品药品监督管理局对吉利德的两款HIV试验性药物GS-1720和GS-4182实施了临床暂停，原因是发现部分参与者出现CD4+T细胞和绝对淋巴细胞计数下降的安全信号 [3] - 受此消息影响，吉利德股价下跌2.91美元，跌幅2.58%，收于110.09美元 [3] 法律事务 - Pomerantz律师事务所正在代表吉利德的投资者进行调查，投资者可联系Danielle Peyton参与集体诉讼 [1][6] - Pomerantz律师事务所在公司、证券和反垄断集体诉讼领域享有盛誉，拥有85年历史，曾为证券欺诈受害者赢得数百万美元赔偿 [4]

法国股指初步收跌0.28%，意大利股指初步收涨0.14%、银行指数涨0.77%，英国股指初步收涨0.12%。 德国DAX 30指数初步收跌0.34%，报23354.81点。 ...

欧洲STOXX 600指数初步收跌0.31%，报540.56点。 欧元区STOXX 50指数初步收跌0.35%，报5270.29点。 富时泛欧绩优300指数初步收跌0.35%，报2142.68点。 ...

美国财政部拍卖四周期国债，得标利率4.060%（6月12日报4.080%），投标倍数3.15（前次为3.22）。 拍卖八周期国债，得标利率4.470%（6月12日报4.380%），投标倍数2.70（前次为2.67）。 美国周四将休市，拍卖活动较以往提前一天进行。 ...

据日本媒体报道，日本制铁公司18日宣布已完成对美国钢铁公司的收购，将其纳为全资子公司。报道 说，日铁当天完成收购美钢全部股份，共支付约141亿美元收购费用，并已完成收购所需的所有手续。 此外，日铁还承诺不更改美钢的公司名称；不将美钢总部迁离匹兹堡；对美钢的投资不毁约、不缩水、 不推迟；不关闭或暂停工厂；美国政府通过获得"黄金股"可对上述情形的违约行为行使否决权等。为完 成收购，日铁与美钢两家公司此前已与美国政府签署国家安全协定，承诺2028年前对美钢投资约110亿 美元，并向美国政府发放可对企业重要事项行使否决权的"黄金股"。(新华社) ...

美国财政部拍卖四周期国债，得标利率4.060%，投标倍数3.15。拍卖八周期国债，得标利率4.470%，投 标倍数2.70。美国周四将休市，拍卖活动较以往提前一天进行。 ...